Investigation Report on China's Ganglioside Market 2010-2019

Aug 06, 2015, 09:10 ET from Research and Markets

DUBLIN, Aug. 06, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/cfjcmw/investigation) has announced the addition of the "Investigation Report on China's Ganglioside Market, 2010-2019" report to their offering.

Cardia-cerebrovascular disease is the first big disease with a mortality rate of 20% in the world and over 40% in China. Besides, as most cardia-cerebrovascular diseases are chronic diseases, long-term treatment is needed, which has forced the big market of cardia-cerebrovascular chemicals. As the major varieties of chemicals for the treatment of hypertension, hyperlipidemia and thrombusare are dominated by foreign enterprises, local enterprises have no advantages. However, there are four domestic varieties in the field of vasodilation drugs and neuronprotective agents, among which ganglioside is included.

Ganglioside preparations first came to market in Italy in the 1980s and were marketed into China by TRB Pharma S.A. and TRB Pharma Ind Quimica E Farmaceutica Ltda under the trade name of SYGEN at the end of 1990s. In Nov. 2004, Qilu Pharmaceutical Co., Ltd became the first approved manufacturer of the active pharmaceutical ingredients (APIs) and injection of ganglioside sodium and power-injection under the trade name of Shenjie later. Currently, there are 7 approved manufacturers of ganglioside sodium in China, among which Qilu Pharmaceutical Co., Ltd, Medical University Pharmaceutical Co., Ltd, Beijing Science Sun Pharmaceutical Co., Ltd, Changchun Xiangtong Pharmaceutical Co., Ltd and Wellso Pharmaceutical take the lion's share.

The marketing of domestic ganglioside injection has improved the breed structure of nervous system drugs and its market share for sales value sales volume has grown fast driven by academic education and product propaganda. For over two years, the wide use of ganglioside injection for the treatment of cerebral apoplexy, child cerebral palsy, dementia and spinal cord injury has further driven the rapid growth of nervous system drugs in hospitals.

According to this market survey, the sales value of ganglioside in China rose from less than CNY 70 million in 2005 to CNY 1.76 billion in 2014, CAGR during this period reaching up to 44.5%. the market size of ganglioside is expected to keep growing in the next few years in China.

Key Topics Covered:

1 Related Concepts of Ganglioside

2 Market Profile of Ganglioside in China

3 Survey on Sales Status of Ganglioside in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Ganglioside in China, 2010-2014

5 Survey on Dosage Forms of Ganglioside in China, 2010-2014

6 Reference Price of Ganglioside in Chinese Hospitals in 2014

7 Major Manufacturers of Ganglioside in Chinese Market, 2010-2014

8 Market Outlook of Ganglioside in China, 2015-2019

Companies Mentioned

- Qilu Pharmaceutical Co., Ltd
- Medical University Pharmaceutical Co., Ltd
- Beijing Science Sun Pharmaceutical Co., Ltd
- Changchun Xiangtong Pharmaceutical Co., Ltd
- Wellso Pharmaceutical, TRB Pharma

For more information visit http://www.researchandmarkets.com/research/cfjcmw/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com